



**68°** CONGRESSO NAZIONALE **SIGG**

Ritorno al futuro

FIRENZE, 13-16 DICEMBRE 2023  
PALAZZO DEI CONGRESSI




# **SIMPOSIO YES**

## **SVALVOLARE IN GERIATRIA: UNA QUESTIONE aTAVIca**

**A qualcuno piace fragile - TAVI o non TAVI?**

**Luigi Spadafora, MD**

**Cardiology Fellow, Sapienza University of Rome-Latina**



Nel caso del nostro  
paziente, stenosi aortica  
severa High-Gradient

2021 ESC/EACTS Guidelines for the management of valvular heart disease. *European Heart Journal*, Volume 43, Issue 7, 14 February 2022





A) Symptomatic aortic stenosis	Class <sup>b</sup>	Level <sup>c</sup>
Intervention is recommended in symptomatic patients with severe, high-gradient aortic stenosis [mean gradient $\geq 40$ mmHg, peak velocity $\geq 4.0$ m/s, and valve area $\leq 1.0$ cm <sup>2</sup> (or $\leq 0.6$ cm <sup>2</sup> /m <sup>2</sup> )]. <sup>235,236</sup>	<b>I</b>	<b>B</b>
Intervention is recommended in symptomatic patients with severe, low-flow (SVI $< 35$ ml/m <sup>2</sup> ), low-gradient ( $< 40$ mmHg) aortic stenosis with reduced ejection fraction ( $< 50\%$ ), and evidence of flow (contractile) reserve. <sup>32,237</sup>	<b>I</b>	<b>B</b>
Intervention should be considered in symptomatic patients with low-flow, low-gradient ( $< 40$ mmHg) aortic stenosis with normal ejection fraction after careful confirmation that the aortic stenosis is severe <sup>d</sup> (Figure 3).	<b>IIa</b>	<b>C</b>
Intervention should be considered in symptomatic patients with low-flow, low-gradient severe aortic stenosis and reduced ejection fraction without flow (contractile) reserve, particularly when CCT calcium scoring confirms severe aortic stenosis.	<b>IIa</b>	<b>C</b>

**Nel nostro caso:**

**Stenosi aortica High gradient + Sintomi + AVA  $< 1$  cm<sup>2</sup> ->**

**Indicazione a trattamento invasivo in classe I B**

2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), *European Heart Journal*, Volume 43, Issue 7, 14 February 2022



# Come procedere?



None of the options are correct!






# TERAPIA MEDICA DELLA STENOSI AORTICA

- Per la Stenosi aortica non esistono terapie disease-modifying
- La terapia medica è sovrapponibile a quella dell'insufficienza cardiaca
- Particolare attenzione va prestata ai vasodilatatori periferici e alla terapia antiipertensiva (titolazione graduale)
- Particolare attenzione va prestata allo stato volemico





*Eur Heart J*, Volume 43, Issue 29, 1 August 2022, Pages 2729–2750, <https://doi.org/10.1093/eurheartj/ehac105>

The content of this slide may be subject to copyright: please see the slide notes for details.



Categories	Favourable	Intermediate	Unfavourable		
<b>Leaflet calcification</b>	<u>Symmetrically calcified leaflets</u> 	<u>Asymmetrically/heavily calcified leaflets</u> 	<u>Calcified raphe &amp; Excess leaflet calcification</u> 		
<b>LVOT calcification</b>	<u>None</u> 	<u>Mild-Moderate</u> 	<u>Severe</u> 		
<b>Risk of conduction disturbance</b>	<u>Low contact pressure</u> 	<u>Long membranous septum</u> 	<u>High contact pressure</u> 	<u>Short membranous septum</u> 	<u>Pre-existing RBBB</u> 
<b>Others</b>	<u>Horizontal aorta</u> 	<u>Narrow SOV low coronary ostia</u> 	<u>Noncalcified aortic valve</u> 	<u>Extreme annular dimension</u> 	

**Figure 2** Anatomical risk stratification of native aortic valve morphology. The category (favourable, intermediate, unfavourable) indicates the suitability for transcatheter aortic valve implantation. RBBB, right bundle branch block; LVOT, left ventricular outflow tract; SOV, sinus of Valsalva.

Which patients with aortic stenosis should be referred to surgery rather than transcatheter aortic valve implantation?, European Heart Journal, Volume 43, Issue 29, 1 August 2022





## ASSESSMENT-PRE TAVI

### TC cuore, aorta e vasi periferici:

- Anatomia dell'asse iliaco-femorale favorevole per TAVI
- Buona distanza tra osti coronarici e anulus valvolare
- Dimensioni dell'anulus compatibili con TAVI

### Rischio operatorio:

- STS PROM 3%

### Presenza di fragilità

Età > 75 aa

### Coronarografia:

- Non evidenza angiografica stenosi coronariche

**INVIO DEL PAZIENTE A TAVI**





**68°** CONGRESSO NAZIONALE **SIGG**


Ritorno al futuro

FIRENZE, 13-16 DICEMBRE 2023  
PALAZZO DEI CONGRESSI



## CVG PRE-TAVI





**Impianto con successo di valvola Edwards Sapien 3 29 mm**

**Nessuna complicanza intra-procedurale**






## MONITORAGGIO POST-OPERATORIO

**Durante la degenza in UTIC e successivamente in reparto:**

- Valori di emoglobina stabili, accesso femorale in ordine
- Non segni di deficit neurologici focali
- Non alterazioni della conduzione intra-ventricolare, persistenza del ritmo da FA normofrequente
- Valori di creatinina stabili nel decorso post-operatorio



## TAVI: PRINCIPALI COMPLICANZE




Grube, E, Sinning, J. The “Big Five” Complications After Transcatheter Aortic Valve Replacement: Do We Still Have to Be Afraid of Them?\*. *J Am Coll Cardiol Interv.* 2019 Feb, 12 (4) 370–372.





## TAVI: PRINCIPALI COMPLICANZE





## TAVI: PRINCIPALI COMPLICANZE

JACC: CARDIOVASCULAR INTERVENTIONS  
© 2019 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION  
PUBLISHED BY ELSEVIER

VOL. 12, NO. 4, 2019

### STRUCTURAL

# Impact of Short-Term Complications on Mortality and Quality of Life After Transcatheter Aortic Valve Replacement



Suzanne V. Arnold, MD, MHA,<sup>a</sup> Yiran Zhang, MS,<sup>b</sup> Suzanne J. Baron, MD, MSc,<sup>a</sup> Thomas C. McAndrew, PhD,<sup>b</sup> Maria C. Alu, MS,<sup>b</sup> Susheel K. Kodali, MD,<sup>b</sup> Samir Kapadia, MD,<sup>c</sup> Vinod H. Thourani, MD,<sup>d</sup> D. Craig Miller, MD,<sup>e</sup> Michael J. Mack, MD,<sup>f</sup> Martin B. Leon, MD,<sup>b</sup> David J. Cohen, MD, MSc<sup>a</sup>







### RIVALUTAZIONE ECOCARDIOGRAFICA POST-OPERATORIA

Gpmed 6-8 mmHg

V max 1.6-1.8 m/s

VTI 37.6 cm

**NETTO MIGLIORAMENTO  
DEL QUADRO  
EMODINAMICO**





## TERAPIA ANTITROMBOTICA

### Transcatheter aortic valve implantation

OAC is recommended lifelong for TAVI patients who have other indications for OAC.<sup>501 f</sup>

Lifelong SAPT is recommended after TAVI in patients with no baseline indication for OAC.<sup>495,496,521</sup>

Routine use OAC is not recommended after TAVI in patients with no baseline indication for OAC.<sup>497</sup>

I

B

I

A

III

B





CHA<sub>2</sub>DS<sub>2</sub>-VASc Score

← Back    ★

CALCULATOR    NEXT STEPS    EVIDENCE    CREATOR

**CHF** history    No 0    Yes +1

Hypertension history    No 0    Yes +1

Stroke/TIA/  
thromboembolism  
history    No 0    Yes +2

Vascular disease history  
(prior MI, peripheral  
arterial disease)    No 0    Yes +1

**RESULT**    >>>    ✓

**4 points**

Stroke risk was 4.8% per year in >90,000 patients (the Swedish Atrial Fibrillation Cohort Study) and 6.7% risk of stroke/TIA/systemic embolism.

One recommendation suggests a 0 score for men or 1 score for women (no clinical risk factors) is "low" risk and may not require anticoagulation; a 1 score for men or 2 score for women is "low-moderate" risk and should consider antiplatelet or anticoagulation; and a score ≥2 for men or ≥3 for women is "moderate-high" risk and should otherwise be an anticoagulation candidate.

HAS-BLED Score

← Back    ★

CALCULATOR    NEXT STEPS    EVIDENCE    CREATOR

>3x normal

Stroke history    No 0    Yes +1

Prior major bleeding or  
predisposition to bleeding    No 0    Yes +1

Labile INR  
Unstable/high INRs, time in  
therapeutic range <60%    No 0    Yes +1

Age >65    No 0    Yes +1

Medication usage  
predisposing to bleeding  
Aspirin, clopidogrel, NSAIDs    No 0    Yes +1

Alcohol use  
≥8 drinks/week    No 0    Yes +1

**RESULT**    ^

**1 points** Relatively low risk of major bleeding.

Si optava per terapia anticoagulante con Edoxaban 30 mg/die per:

- Monosomministrazione (a differenza di Apixaban e Dabigatran)
- Non necessità di assunzione concomitante con cibo (a differenza di Rivaroxaban)-> paziente inappetente
- eGFR secondo CDK-EPI < 50 ml/min



68° CONGRESSO NAZIONALE SIGG


Ritorno al futuro

FIRENZE, 13-16 DICEMBRE 2023  
PALAZZO DEI CONGRESSI




## OTTIMIZZAZIONE DELLA TERAPIA MEDICA

- Bisoprololo 2.5 mg/die
- Empaglifozin 10 mg/die



Gheorghiade M et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005





Ross JJR, Braunwald. 1968.



## TAVI VS TERAPIA MEDICA: IMPATTO ECONOMICO

Valvular heart disease

### openheart Severe symptomatic aortic stenosis: medical therapy and transcatheter aortic valve implantation (TAVI) – a real-world retrospective cohort analysis of outcomes and cost-effectiveness using national data

Phillip M Freeman,<sup>1,2</sup> Majd B Protsy,<sup>1</sup> Omar Aldalati,<sup>3</sup> Richard A Anderson,<sup>5</sup> Dave Smith<sup>3,4</sup>

**Main outcome measures:** Survival, hospital admission frequency and length of stay, primary care visits, and cost-effectiveness.

**Results:** TAVI patients were significantly older (81.8 vs 79.2), more likely to be male (59.1% vs 49.3%), baseline comorbidities were balanced. Mortality in TAVI versus STD was 28% vs 70% at 1000 days follow-up. There were significantly more hospital admissions per year in the TAVI group prior to TAVI/STD (1.5 (IQR 1.0–2.4) vs 1.0 (IQR 0.5–1.5)). Post TAVI/STD, the TAVI group had significantly lower hospital admissions (0.3 (IQR 0.0–1.0) vs 1.2 (IQR 0.7–3.0)) and lengths of stay (0.4 (IQR 0.0–13.8) vs 11.0 (IQR 2.5–28.5),  $p < 0.05$ ). The incremental cost-effectiveness ratio (ICER) for TAVI was £10 533 per quality-adjusted life year (QALY).

While this is a relatively small study, it represents an important step in real-world long-term outcomes of either medical therapy or TAVI in a high-risk population with severe symptomatic aortic stenosis. It also supports clinical trial findings of improved outcomes in patients managed with TAVI and for the first time reveals that TAVI is a cost-effective procedure in real-world practice.

**Conclusions:** TAVI patients were more likely to survive and avoid hospital admissions compared with the medically managed STD group. The ICER for TAVI was £10 533 per QALY, making it a cost-effective procedure.





68° CONGRESSO NAZIONALE SIGG

Ritorno al futuro

FIRENZE, 13-16 DICEMBRE 2023  
PALAZZO DEI CONGRESSI



Support us →

The Guardian  
News website of the year

News Opinion Sport Culture Lifestyle



**Mick Jagger**

## Mick Jagger says he is on the mend following heart valve procedure

Rolling Stones frontman underwent procedure in New York earlier this week, according to report in Billboard magazine

*Reuters*

Fri 5 Apr 2019 18.54 CEST

2019



**F** Forbes

## Mick Jagger 'On The Mend' After Reportedly Getting A New Aortic Valve

The lead singer for the Rolling Stones reportedly just underwent a successful transcatheter aortic valve replacement (TAVR).

5 apr 2019







US World Politics Business Opinion Health Entertainment Style Travel Sports Video

# The Rolling Stones are hitting the road next year on a tour sponsored by AARP

By Dan Heching, CNN

🕒 1 minute read · Updated 3:29 PM EST Wed November 22, 2023

